ArticleLife (Basel, Switzerland)2024
Comparison of Lung-RADS Version 2022 and British Thoracic Society Guidelines in Classifying Solid Pulmonary Nodules Detected at Lung Cancer Screening CT.
Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Expert Consensus on Precision Management of Pulmonary Nodules (2026 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLung cancer screening is critical for early detection and management, particularly through the use of computed tomography (CT). This study aims to compare the Lung Imaging Reporting and Data System (Lung-RADS) Version 2022 with the British Thoracic Society (BTS) guidelines in classifying solid pulmonary nodules detected at lung cancer screening CT examinations. MATERIALS AND
methodsThis retrospective study included 224 patients who underwent lung cancer screening CT between 2016 and 2022 and had a reported solid pulmonary nodule. A fellowship-trained thoracic radiologist reviewed the CT images, characterizing nodules by size, location, margins, attenuation, calcification, growth at follow-up, and final pathologic diagnosis if malignant. The sensitivity and specificity of Lung-RADS Version 2022 in detecting malignant nodules were compared with those of the BTS guidelines using the McNemar test.
resultsOf the 224 patients, 198 (88%) had nodules deemed benign, while 26 (12%) had malignant nodules. The Lung-RADS Version 2022 resulted in higher specificity than the BTS guidelines (85% vs. 65%,
conclusionsCompared with the BTS guidelines, Lung-RADS Version 2022 reduces the number of false-positive screening CT examinations while maintaining high sensitivity for detecting malignant solid pulmonary nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.